Immune checkpoint inhibitors (ICIs), including anti-PD-1, anti-PD-L1, and anti-CTLA-4 antibodies, function by blocking inhibitory pathways to activate T cells, enabling tumor cell attack while increasing susceptibility to immune-related adverse events (irAEs) such as pneumonitis.17 Here, CTLA4 is linked to pneumonitis.